Promotion of bladder cancer development and progression by androgen receptor signals

Journal of the National Cancer Institute

Volumn 99, Issue 7, 2007, Pages 558-568

  Miyamoto, Hiroshi ^a   Yang, Zhiming ^a   Chen, Yei Tsung ^a   Ishiguro, Hitoshi ^b   Uemura, Hiroji ^b   Kubota, Yoshinobu ^b   Nagashima, Yoji ^b   Chang, Yu Jia ^a   Hu, Yueh Chiang ^a   Tsai, Meng Yin ^c   Yeh, Shuyuan ^a   Messing, Edward M ^a   Chang, Chawnshang ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXY 1,7 BIS(3,4 DIMETHOXYPHENYL) 1,4,6 HEPTATRIEN 3 ONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; ASC J 9; FLUTAMIDE; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANDROGEN DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL CULTURE; CANCER INHIBITION; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; BLADDER TUMOR; DISEASE COURSE; DISEASE MODEL; GENETICS; MOUSE MUTANT; PATHOLOGY; SEXUAL DEVELOPMENT;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, ANDROGEN; SEX CHARACTERISTICS; URINARY BLADDER NEOPLASMS;

EID: 34247637194     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk113     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990;82:1036-40.
3. Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer 1972;8:587-94.
4. Shen J, Wanibuchi H, Waalkes MP, Salim EI, Kinoshita A, Yoshida K, et al. A comparative study of the sub-chronic toxic effects of three organic arsenical compounds on the urothelium in F344 rats; gender-based differences in response. Toxicol Appl Pharmacol 2006;210:171-80.
5. Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, Duggan H, et al. Cancer risks from arsenic in drinking water. Environ Health Perspect 1992;97:259-67.
6. Chang C, Kokontis J, Liao S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988;240:324-6.
7. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
8. Salmi A, Santti R, Gustafsson J-Å, Mäkelä S. Co-localization of androgen receptor with estrogen receptor β in the lower urinary tract of the male rat. J Urol 2001;166:674-7.
9. Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004;64:383-8.
10. Imaoka S, Yoneda Y, Sugimoto T, Ikemoto S, Hiroi T, Yamamoto K, et al. Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: Detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction. Cancer Lett 2001;166:119-23.
11. Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, Takenaka T. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol 1997;31:360-4.
12. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
13. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
14. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004;61:332-53.
15. Miyamoto H, Messing EM, Chang C. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Nat Clin Pract Oncol 2005;2:236-7.
16. Elliott AY, Bronson DL, Stein N, Fraley EE. In vitro cultivation of epithelial cells derived from tumors of the human urinary tract. Cancer Res 1976;36:365-9.
17. Miyamoto H, Marwah P, Marwah A, Yang Z, Chung C-Y, Altuwaijri S, et al. Identification of steroid derivatives that function as potent antiandrogens. Int J Cancer 2005;117:866-72.
18. Yeh S, Hu Y-C, Wang P-H, Xie C, Xu Q, Tsai M-Y, et al. Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med 2003;198:1899-908.
19. Yeh S, Tsai M-Y, Xu Q, Mu X-M, Lardy H, Huang K-E, et al. Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A 2002;99:13498-503.
20. Miyamoto H, Kubota Y, Shuin T, Torigoe S, Dobashi Y, Hosaka M. Expression of transforming growth factor-beta 1 in human bladder cancer. Cancer 1995;75:2565-70.
21. Miyoshi Y, Uemura H, Fujinami K, Miyamoto H, Miyoshi Y, Ishiguro H, et al. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003;56:280-6.
22. Miyamoto H, Marwah P, Marwah A, Lardy H, Chang C. 3β-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc Natl Acad Sci U S A 2003;100:4440-4.
23. Ohtsu H, Xiao Z, Ishida J, Nagai M, Wang H-K, Itokawa H, et al. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem 2002;45:5037-42.
24. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems (3rd ed.). Protocol 11. Test evaluation. Cancer Chemother Rep 1972;3:47-52.
25. Chang C, Chen Y-T, Yeh S-D, Xu Q, Wang R-S, Guillou F, et al. Infertility with defective spermatogenesis and hypotestosternemia in male mice lacking the androgen receptor in Sertoli cells. Proc Natl Acad Sci U S A 2004;101:6876-81.
26. Ohtani M, Kakizoe T, Nishio Y, Sato S, Sugimura T, Fukushima S, et al. Sequential changes of mouse bladder epithelium during induction of invasive carcinoma by N-butyl-N(-4-hydroxybutyl nitrosamine. Cancer Res 1986;46:2001-4.
27. Shiina H, Matsumoto T, Sato T, Igarashi K, Miyamoto J, Takamasa S, et al. Premature ovarian failure in androgen receptor-deficient mice. Proc Natl Acad Sci U S A 2006;103:224-9.
28. Chen F, Langenstroer P, Zhang G, Iwamoto Y, See WA. Androgen dependent regulation of bacillus Calmette-guerin induced interleukin-6 expression in human transitional carcinoma cell lines. J Urol 2003;170:2009-13.
29. Yang Z, Chang Y-J, Yu I-C, Yeh S, Wu C-C, Miyamoto H, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med. In press 2007.
30. Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A. et al. The androgen derivative 5α-androstane-3β,17β-diol inhibits prostate cancer cell migration through activation of the estrogen receptor β subtype. Cancer Res 2005;65:5445-53.
31. Laor E, Schiffman ZJ, Braunstein JD, Reid RE, Tolia BM, Koss LG, et al. Androgen receptors in bladder tumors. Urology 1985;25:161-3.
32. Noronha RFX, Roa BR. Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans. Urology 1986;28:401-3.
33. Zhuang Y-H, Bläuer M, Tammela T, Tuohimaa P. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 1997;30:556-62.
34. Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: Identification of molecular targets in bladder cancer. Br J Cancer 2003;89:2172-7.
35. Smith SC, Oxford G, Theodorescu D. The promise of gene-expression in bladder cancer: A clinician's guide. BJU Int 2005;95:874-80.